Nintedanib Accordpharma (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting fibroblast proliferation, extracellular matrix formation, and abnormal blood‑vessel growth. This multi‑target inhibition reduces fibrotic tissue development in the lungs and can limit tumor blood supply in certain cancers.

The dosage of Nintedanib Accordpharma is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and concomitant medications. No fixed regimen is provided here; the prescriber will set the appropriate dose and schedule.

Safety data for Nintedanib during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally recommended to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another oral antifibrotic. While both aim to slow disease progression, Nintedanib targets multiple tyrosine kinases, offering broader inhibition of fibroblast activity and angiogenesis, whereas pirfenidone’s mechanism involves modulation of cytokine production and oxidative stress. Choice depends on patient tolerance, comorbidities and physician judgment.

Nintedanib should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Nintedanib is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the timing without medical advice.

Serious risks include hepatotoxicity (significant liver enzyme elevation or liver injury), severe bleeding events (especially when combined with anticoagulants), and cardiovascular complications such as arterial thromboembolism or myocardial infarction. Patients should be monitored regularly for liver function, signs of bleeding, and cardiovascular symptoms.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. It should also be avoided in individuals with severe hepatic impairment, uncontrolled bleeding disorders, or those who are pregnant or breastfeeding without a clear benefit outweighing the risk.